Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis

The value of neoadjuvant chemotherapy (NAC) has not yet been fully defined. We aimed to systematically evaluate the influence of neoadjuvant chemotherapy (NAC) on survival and complete cytoreduction after debulking surgery in advanced epithelial ovarian cancer (AEOC) patients. We searched PubMed, Em...

Full description

Bibliographic Details
Main Authors:	Zeng, Long-Jia, Xiang, Chun-Lin, Gong, Yi-Zhen, Kuang, Yan, Lu, Fang-Fang, Yi, Su-Yi, Zhang, Yue, Liao, Meng
Format:	Online
Language:	English
Published:	Nature Publishing Group 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090201/

id	pubmed-5090201
recordtype	oai_dc
spelling	pubmed-50902012016-11-08 Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis Zeng, Long-Jia Xiang, Chun-Lin Gong, Yi-Zhen Kuang, Yan Lu, Fang-Fang Yi, Su-Yi Zhang, Yue Liao, Meng Article The value of neoadjuvant chemotherapy (NAC) has not yet been fully defined. We aimed to systematically evaluate the influence of neoadjuvant chemotherapy (NAC) on survival and complete cytoreduction after debulking surgery in advanced epithelial ovarian cancer (AEOC) patients. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for the randomized controlled trials (RCTs) comparing NAC and primary debulking surgery (PDS) in AEOC patients. The last search date is February 25, 2016. Cochrane systematic evaluation was used to evaluate bias risk of included studies. RevMan 5.3 software was used for statistical analysis. A total of 4 RCTs involving 1922 patients were included. Compared with PDS, NAC may contribute to the completeness of debulking removal [no residual disease (RR: 2.37; 95%CI: 1.94–2.91; P<0.00001), residual disease ≤1 cm (RR: 1.28; 95%CI: 1.04–1.57; P = 0.02), optimal cytoreduction rate (RR: 1.76; 95%CI: 1.57–1.98; P<0.00001)], but there were no significant differences in both groups with regard to overall survival (HR: 0.94; 95%Cl: 0.81–1.08; P = 0.38) and progression-free survival (HR: 0.89; 95%Cl: 0.77–1.03; P = 0.12). This meta-analysis indicates that the higher rate of optimal debulking made NAC more favorable as a treatment option for AEOC patients with non-inferior survival compared with PDS. Nature Publishing Group 2016-11-02 /pmc/articles/PMC5090201/ /pubmed/27804983 http://dx.doi.org/10.1038/srep35914 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Zeng, Long-Jia Xiang, Chun-Lin Gong, Yi-Zhen Kuang, Yan Lu, Fang-Fang Yi, Su-Yi Zhang, Yue Liao, Meng
spellingShingle	Zeng, Long-Jia Xiang, Chun-Lin Gong, Yi-Zhen Kuang, Yan Lu, Fang-Fang Yi, Su-Yi Zhang, Yue Liao, Meng Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
author_facet	Zeng, Long-Jia Xiang, Chun-Lin Gong, Yi-Zhen Kuang, Yan Lu, Fang-Fang Yi, Su-Yi Zhang, Yue Liao, Meng
author_sort	Zeng, Long-Jia
title	Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
title_short	Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
title_full	Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
title_fullStr	Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
title_full_unstemmed	Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
title_sort	neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer: a meta-analysis
description	The value of neoadjuvant chemotherapy (NAC) has not yet been fully defined. We aimed to systematically evaluate the influence of neoadjuvant chemotherapy (NAC) on survival and complete cytoreduction after debulking surgery in advanced epithelial ovarian cancer (AEOC) patients. We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials for the randomized controlled trials (RCTs) comparing NAC and primary debulking surgery (PDS) in AEOC patients. The last search date is February 25, 2016. Cochrane systematic evaluation was used to evaluate bias risk of included studies. RevMan 5.3 software was used for statistical analysis. A total of 4 RCTs involving 1922 patients were included. Compared with PDS, NAC may contribute to the completeness of debulking removal [no residual disease (RR: 2.37; 95%CI: 1.94–2.91; P<0.00001), residual disease ≤1 cm (RR: 1.28; 95%CI: 1.04–1.57; P = 0.02), optimal cytoreduction rate (RR: 1.76; 95%CI: 1.57–1.98; P<0.00001)], but there were no significant differences in both groups with regard to overall survival (HR: 0.94; 95%Cl: 0.81–1.08; P = 0.38) and progression-free survival (HR: 0.89; 95%Cl: 0.77–1.03; P = 0.12). This meta-analysis indicates that the higher rate of optimal debulking made NAC more favorable as a treatment option for AEOC patients with non-inferior survival compared with PDS.
publisher	Nature Publishing Group
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090201/
_version_	1613707649758527488

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis

Similar Items